Babatasi G, Massetti M, Bhoyroo S, Cleron S, Agostini D, Lebreton P, Gérard J L, Zerr C, Scanu P, Grollier G, Potier J C, Khayat A
Service de Chirurgie Thoracique et Cardio-Vasculaire, CHU Caen Côte de Nacre, CAEN, France.
Ann Cardiol Angeiol (Paris). 1996 May;45(5):249-55.
The global results of various series of heart transplantation (HT) are essential to assess the life expectancy provided by this technique. Due to the increasing graft shortage, it appears essential to very strictly candidates for HT.
From March 8, 1989 to December 7, 1994, 75 orthotopic Hts were performed in 62 men and 12 women (1 case of retransplantation). The mean age was 47.46 +/- 15.02 years (range: 2.5-66 years). Four patients were younger than 10 years and 22 were older than 60 years. Our series included more cases of ischaemic heart disease (36) than dilated cardiomyopathies (33), with a history of cardiac surgery in almost one quarter (20) of patients with ischaemic heart disease.
The immediate postoperative survival rate was 94.7% with 3 deaths attributable to refractory pulmonary hypertension associated with graft failure and one death related to postoperative tamponade. Five other patients died during the following 3 months, increasing the mean global survival to 88%. After a mean follow-up of 2.1 years (maximum 5.8 years), the actuarial 5-year survival rate was 56.8%. Eleven patients died between 4 and 38 months (mean: 18.2 months). Two deaths were due to cancers, 4 were due to septicaemia, another 4 were due to rejection and finally 1 was due to meningeal haemorrhage. The frequency (19) of reoperations for clot removal was due to the large number of patients with a history of previous heart surgery (20).
Strict recipient selection, possibly based on 123I-MIBG scintigraphy, the use of pulsatile circulatory assistance systems, improved CMV, morphometry and donor-recipient age matching, should optimize the results of a technique, whose efficacy is confirmed in this series.
各类心脏移植(HT)系列的全球结果对于评估该技术所提供的预期寿命至关重要。由于供体短缺日益严重,对心脏移植候选人进行非常严格的筛选显得至关重要。
从1989年3月8日至1994年12月7日,对62名男性和12名女性(1例再次移植)进行了75例原位心脏移植。平均年龄为47.46±15.02岁(范围:2.5 - 66岁)。4例患者年龄小于10岁,22例患者年龄大于60岁。我们的系列中缺血性心脏病患者(36例)比扩张型心肌病患者(33例)更多,近四分之一(20例)缺血性心脏病患者有心脏手术史。
术后即刻生存率为94.7%,3例死亡归因于与移植失败相关的难治性肺动脉高压,1例死亡与术后心包填塞有关。另外5例患者在接下来的3个月内死亡,平均总生存率提高到88%。平均随访2.1年(最长5.8年)后,精算5年生存率为56.8%。11例患者在4至38个月(平均:18.2个月)之间死亡。2例死于癌症,4例死于败血症,另外4例死于排斥反应,最后1例死于脑膜出血。因清除血栓而再次手术的频率(19次)是由于既往有心脏手术史的患者数量众多(20例)。
严格的受体选择,可能基于123I - MIBG闪烁扫描、使用搏动性循环辅助系统、改善巨细胞病毒感染情况、形态测量以及供体 - 受体年龄匹配,应能优化该技术的结果,本系列已证实其有效性。